Arrowhead Drug ARO-DIMER-PA Cuts LDL 54%, Triglycerides 73% With Single Injection at AHA
· techtimes.com · popularity 18/100 · 0 similar stories today
Read the original at techtimes.com →
Summary
ARO-DIMER-PA, Arrowhead Pharmaceuticals' investigational dual-gene RNAi drug, posted 54% LDL cholesterol and 73% triglyceride reductions in Phase 1 single-dose data presented at the American Heart Association Scientific Sessions 2026, the first clinical proof a single injection can silence both PCSK9 and APOC3 simultaneously.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 10.